A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

Exclusion Criteria

• •Previous treatment with Abatacept (Orencia)
• •Previous treatment with rituximab, tocilizumab, tofacitinib, sarilumab, or anakinra
• •Previous treatment with IV immunoglobulin, plasmapheresis, or alkylating agents such as cyclophosphamide
• •Intraarticular or parenteral corticosteroids within 4 weeks of screening
• •Rheumatic autoimmune disease other than Rheumatoid Arthritis, including Systemic Lupus Erythematosus, primary Sjogren syndrome, spondyloarthritis, systemic sclerosis, dermatomyositis, mixed connective tissue disease, or vasculitis
• •Non-rheumatic auto-immune disease including inflammatory bowel disease, psoriasis, multiple sclerosis
• •Recurrent or chronic bacterial, viral, fungal, mycobacterial, or other infections including Human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C, latent tuberculosis (TB) (TB not adequately treated)
• •Primary or secondary immunodeficiency
• •Current, uncontrolled renal, gastrointestinal, endocrine, pulmonary, cardiac, or neurologic disease
• •History of malignancy within 10 years prior to screening, except for appropriately treated carcinoma in situ of the cervix or non-melanoma skin carcinoma
• •History of alcohol, drug, or chemical abuse within 1 year prior to screening
• •1. estimated glomerular filtration rate (eGFR) \<30ml/min
• •2. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) \>1.5 times upper limit of normal
• •Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery during the study
• •Immunization with a live/attenuated vaccine within 4 weeks prior to screening
• •Pregnant or nursing women, or women of child bearing potential who plan to become pregnant prior to 14 weeks after the last dose of abatacept treatment
• •Patients of reproductive potential not willing to use an effective method of contraception
• •Prisoners, or subjects who are compulsory detained